Literature DB >> 35094326

Fluorescence Lifetime Imaging Probes for Cell-Based Measurements of Enzyme Activity.

Sampreeti Jena1, Laurie L Parker2.   

Abstract

Posttranslational modification (PTM) enzymes are important modulators of protein structure and function. They typically act by chemically modifying amino acids, often on side chain functional groups, to change the physiochemical landscape of the protein and thus its biophysical behavior. In particular, protein kinases are enzymes that transfer phosphate from ATP to serine, threonine, or tyrosine in protein substrates. They are key regulators of vital cellular pathways such as survival, proliferation, and apoptosis, and their dysregulation in the context of cancer has been widely investigated for the purpose of development of anticancer drugs. However, several critical questions pertaining to their physiology, such as heterogeneity of kinase signaling within and between cells, and other factors that may play into the mechanisms of drug resistance, remain unanswered. Many of the current strategies to measure kinase activity lack the scope, subcellular resolution, and real-time monitoring ability needed to obtain the type of information needed about their dynamics and localization in cells. While FRET-based biosensors are capable of dynamic single cell imaging, their applications can be limited by difficulties in multiplexing and the inherent inadequacies of steady state measurements. In this chapter, we describe our fluorescence lifetime imaging microscopy (FLIM) probe technology in which peptide kinase substrates, linked to cell-penetrating peptides and labeled with small molecule fluorophores, are used to report kinase activity through time-resolved fluorescence imaging to visualize and quantify changes to the probe's fluorescence lifetime. These can be multiplexed for more than one kinase at a time, and interpretation is not affected by differences in local intensity due to probe uptake and distribution or photobleaching. With careful choice of peptide substrate(s), fluorophore label, and imaging set-up, high specificity and spatiotemporal resolution can be achieved. Due to the mechanism by which the lifetime change occurs, this approach is compatible with other PTMs (such as acetylation, methylation), and so the considerations for kinase FLIM probe design described in this chapter should be broadly applicable for other PTMs as well.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cell-penetrating peptides; Fluorescence lifetime; Fluorescent probes; Kinase activity; Kinase substrates

Mesh:

Substances:

Year:  2022        PMID: 35094326     DOI: 10.1007/978-1-0716-1811-0_9

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  34 in total

Review 1.  Targeting cancer with kinase inhibitors.

Authors:  Stefan Gross; Rami Rahal; Nicolas Stransky; Christoph Lengauer; Klaus P Hoeflich
Journal:  J Clin Invest       Date:  2015-05-01       Impact factor: 14.808

2.  Use of an oriented peptide library to determine the optimal substrates of protein kinases.

Authors:  Z Songyang; S Blechner; N Hoagland; M F Hoekstra; H Piwnica-Worms; L C Cantley
Journal:  Curr Biol       Date:  1994-11-01       Impact factor: 10.834

3.  Assays for tyrosine phosphorylation in human cells.

Authors:  Monica Kruk; Naomi Widstrom; Sampreeti Jena; Nicole L Wolter; John F Blankenhorn; Ibrahim Abdalla; Tzu-Yi Yang; Laurie L Parker
Journal:  Methods Enzymol       Date:  2019-07-24       Impact factor: 1.600

4.  My journey from tyrosine phosphorylation inhibitors to targeted immune therapy as strategies to combat cancer.

Authors:  Alexander Levitzki; Shoshana Klein
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-10       Impact factor: 11.205

5.  Linear motif atlas for phosphorylation-dependent signaling.

Authors:  Martin Lee Miller; Lars Juhl Jensen; Francesca Diella; Claus Jørgensen; Michele Tinti; Lei Li; Marilyn Hsiung; Sirlester A Parker; Jennifer Bordeaux; Thomas Sicheritz-Ponten; Marina Olhovsky; Adrian Pasculescu; Jes Alexander; Stefan Knapp; Nikolaj Blom; Peer Bork; Shawn Li; Gianni Cesareni; Tony Pawson; Benjamin E Turk; Michael B Yaffe; Søren Brunak; Rune Linding
Journal:  Sci Signal       Date:  2008-09-02       Impact factor: 8.192

Review 6.  How do Abl family kinases regulate cell shape and movement?

Authors:  Samuel E Hernández; Maithreyi Krishnaswami; Ann L Miller; Anthony J Koleske
Journal:  Trends Cell Biol       Date:  2004-01       Impact factor: 20.808

Review 7.  Targeted cancer therapy: promise and reality.

Authors:  Shoshana Klein; Alexander Levitzki
Journal:  Adv Cancer Res       Date:  2007       Impact factor: 6.242

Review 8.  Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update.

Authors:  Robert Roskoski
Journal:  Pharmacol Res       Date:  2019-12-17       Impact factor: 7.658

9.  C-abl and bcr are rearranged in a Ph1-negative CML patient.

Authors:  C R Bartram; E Kleihauer; A de Klein; G Grosveld; J R Teyssier; N Heisterkamp; J Groffen
Journal:  EMBO J       Date:  1985-03       Impact factor: 11.598

10.  Global analysis of human nonreceptor tyrosine kinase specificity using high-density peptide microarrays.

Authors:  Yang Deng; Nilda L Alicea-Velázquez; Ludovic Bannwarth; Soili I Lehtonen; Titus J Boggon; Heung-Chin Cheng; Vesa P Hytönen; Benjamin E Turk
Journal:  J Proteome Res       Date:  2014-08-28       Impact factor: 4.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.